Chronic Lymphocytic Leukemia Coverage from Every Angle

Recent News

Dual PI3Kδ/CK1ε Inhibition on CLL T Cells
Predictors of Outcome in Patients with CLL and COVID-19
Can Prognosis Assessments Accurately Predict Time to First Treatment in Early-Stage CLL?
CLL and COVID-19: When May Humoral Immunity Therapy Be Indicated?
Zanubrutinib for Resistant CLL and Small Lymphocytic Lymphoma
Two Decades of Data Confirm Poor Prognosis With Richter Transformation in CLL
EHA25 Virtual: Quality of Life With Duvelisib Versus Ofatumumab in CLL
EHA25 Virtual: Does Administration Sequence of Ibrutinib/Obinutuzumab in CLL Affect Toxicity?
Real-World Study Finds VHA Adopts Novel Agents in CLL Treatment
AACR II: Linking HPV Infection to Skin Cancer in Patients With CLL
EHA25 Virtual: First-Line Ibrutinib/Venetoclax Combination in CLL
EHA25 Virtual: Trial Update on Ibrutinib Plus Umbralisib in Resistant CLL
ASCO20: Venetoclax Plus Obinutuzumab in Treatment-Naive CLL
EHA25 Virtual: Long-Term Results With Acalabrutinib in Treatment-Naive CLL
ASCO20: Final Results From GENUINE Trial of Ublituximab Plus Ibrutinib in CLL
EHA25 Virtual: VENICE-I Findings With Venetoclax in Resistant CLL
EHA25 Virtual: Phase III Trial to Study Acalabrutinib-Based Combination in CLL
ASCO20: Does Early Discontinuation of Venetoclax Affect Outcomes in CLL?
ASCO20: Cirmtuzumab Plus Ibrutinib in Relapsed or Refractory CLL
ASCO20: Final Results From ASCEND Trial of Acalabrutinib in Resistant CLL
ASCO20: Intermittent Scheduling of PI3Kδ Inhibitor in CLL
Chemotherapy-Free Treatment of CLL: Acalabrutinib With or Without Obinutuzumab
Managing CLL During the COVID-19 Pandemic: An International Survey of Experts
Ofatumumab Treatment and Rare Viral Infection of the Brain : A Case Study in CLL
Brazilian Task Force Offers Strategies for Managing COVID-19 and Lymphoid Malignancies
CLL-Related Cognitive Function: Disease Biology or Treatment Effect?
COVID-19 and Untreated Patients With CLL: Case Reports Shed Light on Clinical Risks
Mitochondrial Respiration: A Prognostic Marker of Response to CLL Treatment?
First-Line Ibrutinib Treatment of CLL: 5-Year Follow-up Results
FDA Approves Ibrutinib Plus Rituximab as Initial Treatment of CLL
Health-Related Quality of Life for Patients With CLL Treated With Ibrutinib
Do Longer Reads Equal Better Reads in Analyzing SF3B1 Mutation in CLL?
COVID-19 Infection Reported in Chinese Patient With CLL
Cellular Polarization and Its Impact on Growth of CLL Cells
Venetoclax Therapy and Attainment of Undetectable Minimal Residual Disease in CLL
Machine Modeling as a Predictive Tool for Infection Risk in Patients With CLL
First-Line Treatment With Four-Drug Regimen in Young Patients With CLL
Genomic Analyses May Predict Treatment Outcomes in Patients With CLL
CAPTIVATE Trial of First-Line Ibrutinib Plus Venetoclax in CLL

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.